International Markets - Licensing

Capability & Reach

• Cutting edge commercial  programmes, delivering industry
leading performance.
• Global reach and critical mass in all key international markets
• High commitment to speciality and primary care target
audiences.

ISMO Sales & Marketing strength

• Unrivalled capacity to launch and optimize commercialization
of brands across ISMO regions.
• Outstanding sales and marketing performance with primary
and secondary care brands, (Nexium, Crestor, Arimidex,
Seroquel and Symbicort).
• Therapeutic focus and expertise in CV, GI, Respiratory, Oncology, Neuroscience and Infection.

Key areas of partnering interest

ISMO is interested in national and regional in-licensing opportunities
for late stage, registered and marketed products.

ISMO Licensing works closely with SPBD in assessing and evaluating products and multi-product opportunities for third party agreements covering product acquisitions, in-licensing, co-marketing, co-promotion and distribution agreements.

We have extensive experience of national, regional partnerships and alliances and have our own Alliance Management Group supporting existing deals. ISMO offers an excellent Preferred Partner for High Performance delivery at national and regional levels.

Contacts

Len Holmes,
Jeanette Evans

E-mail:
firstname.lastname@astrazeneca.com
- Replace with authentic names